Medical Update: Lobular Breast Cancer

Invasive lobular breast cancer (ILC) accounts for 10-15% of all breast cancers, with thousands of new diagnoses each year in the US. ILC looks and behaves differently than more common ductal cancers, is under-studied, and requires more clinical research. This session focuses on current standard treatments for ILC, what past research has shown works effectively for it, the research questions that remain, and ways to get involved in advancing understanding by taking part in clinical trials and research studies. Hosted in partnership with the Lobular Breast Cancer Alliance (LBCA).

Rachel C. Jankowitz, MD
Director, Rena Rowan Breast Center at the Perelman Center for Advanced Medicine and the Penn Abramson Cancer Center
Associate Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania


Rachel C. Jankowitz, MD, is an associate professor of clinical medicine in the division of hematology/oncology at the Perelman School of Medicine at the University of Pennsylvania and director of the Rena Rowan Breast Center at the Penn Abramson Cancer Center. Dr. Jankowitz’s clinical practice is focused on caring for people with breast cancer. Her research focuses on invasive lobular breast cancer, endocrine resistance in hormone receptor-positive breast cancer, and breast cancer clinical trials. She has served as a primary investigator or co-investigator for many breast cancer clinical trials and is an active investigator in the Translational Breast Cancer Research Consortium. She is particularly interested in biomarker development and treatment response in those with lobular breast cancer.